+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
328232-95-7,MFCD25976714
Catalog No.:AA01EFOO

328232-95-7 | MK 0557 - Bio-X

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥98%
in stock  
$53.00   $37.00
- +
5mg
≥98%
in stock  
$230.00   $161.00
- +
10mg
≥98%
in stock  
$405.00   $283.00
- +
25mg
≥98%
in stock  
$883.00   $618.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA01EFOO
Chemical Name:
MK 0557 - Bio-X
CAS Number:
328232-95-7
Molecular Formula:
C22H19FN4O3
Molecular Weight:
406.4097
MDL Number:
MFCD25976714
SMILES:
O=C([C@@H]1CC[C@]2(CC1)OC(=O)c1c2cncc1)Nc1ccn(n1)c1ccccc1F
Properties
Computed Properties
 
Complexity:
669  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
30  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
3  
XLogP3:
2.6  

Literature

Title: Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.

Journal: Bioorganic & medicinal chemistry letters 20120415

Title: Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.

Journal: Bioorganic & medicinal chemistry letters 20101201

Title: Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.

Journal: Bioorganic & medicinal chemistry 20091001

Title: Obesity and the central nervous system.

Journal: The Journal of physiology 20070901

Title: NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.

Journal: Obesity (Silver Spring, Md.) 20070801

Title: Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.

Journal: Obesity (Silver Spring, Md.) 20070401

Title: Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.

Journal: Cell metabolism 20061001

Title: Fichtner M, et al. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2738-43.

Title: Erondu N, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006 Oct;4(4):275-82.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 328232-95-7
Building Blocks
More >
Tags:328232-95-7 Molecular Formula|328232-95-7 MDL|328232-95-7 SMILES|328232-95-7 MK 0557 - Bio-X
Catalog No.: AA01EFOO
328232-95-7,MFCD25976714
328232-95-7 | MK 0557 - Bio-X
Pack Size： 1mg
Purity： ≥98%
in stock
$53.00 $37.00
Pack Size： 5mg
Purity： ≥98%
in stock
$230.00 $161.00
Pack Size： 10mg
Purity： ≥98%
in stock
$405.00 $283.00
Pack Size： 25mg
Purity： ≥98%
in stock
$883.00 $618.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA01EFOO
Chemical Name: MK 0557 - Bio-X
CAS Number: 328232-95-7
Molecular Formula: C22H19FN4O3
Molecular Weight: 406.4097
MDL Number: MFCD25976714
SMILES: O=C([C@@H]1CC[C@]2(CC1)OC(=O)c1c2cncc1)Nc1ccn(n1)c1ccccc1F
Properties
Complexity: 669  
Covalently-Bonded Unit Count: 1  
Heavy Atom Count: 30  
Hydrogen Bond Acceptor Count: 6  
Hydrogen Bond Donor Count: 1  
Rotatable Bond Count: 3  
XLogP3: 2.6  
Literature fold

Title: Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.

Journal: Bioorganic & medicinal chemistry letters20120415

Title: Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.

Journal: Bioorganic & medicinal chemistry letters20101201

Title: Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.

Journal: Bioorganic & medicinal chemistry20091001

Title: Obesity and the central nervous system.

Journal: The Journal of physiology20070901

Title: NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.

Journal: Obesity (Silver Spring, Md.)20070801

Title: Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.

Journal: Obesity (Silver Spring, Md.)20070401

Title: Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.

Journal: Cell metabolism20061001

Title: Fichtner M, et al. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2738-43.

Title: Erondu N, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006 Oct;4(4):275-82.

Related Products of of 328232-95-7
Building Blocks More >
263409-78-5
263409-78-5
tert-Butyl N-[2-(4-fluorophenoxy)ethyl]carbamate
AA01EH6A | MFCD24393200
2096331-49-4
2096331-49-4
2-(Benzyloxy)-4-fluoro-5-methylphenylboronic acid
AA01EH9B | MFCD20441835
2096331-22-3
2096331-22-3
2-Chloro-6-(4-methoxybenzyloxy)pyridine-4-boronic acid, pinacol ester
AA01EHCD | MFCD20441902
2096336-18-2
2096336-18-2
2-Fluoro-3-isopropoxy-5-methylphenylboronic acid
AA01EHFS | MFCD19981515
2096334-14-2
2096334-14-2
3-Ethoxy-2-fluoro-4-methoxyphenylboronic acid
AA01EHIO | MFCD18914501
2096334-68-6
2096334-68-6
5-Bromo-4-cyano-2-fluorophenylboronic acid, pinacol ester
AA01EHLP | MFCD18837630
62306-03-0
62306-03-0
3-methyl-2,3-dihydro-1,3-benzothiazol-2-imine hydroiodide
AA01EHOX | MFCD00223182
1020955-83-2
1020955-83-2
3-FLUORO-N-(IMIDAZO[1,2-A]PYRIDIN-2-YLMETHYL)-4-METHYLANILINE
AA01EHSE | MFCD12626556
1374656-03-7
1374656-03-7
rac-tert-butyl N-[(2R,3R)-2-methylpyrrolidin-3-yl]carbamate
AA01EHWH | MFCD24856478
2138032-33-2
2138032-33-2
2-(5-methyl-1,2-oxazol-4-yl)ethan-1-amine hydrochloride
AA01EHZS | MFCD28891250
Submit
© 2017 AA BLOCKS, INC. All rights reserved.